​
​

Adaptimmune Therapeutics (ADAP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Adaptimmune Therapeutics Revenue Highlights

Latest Revenue (Y)

$60.28M

Latest Revenue (Q)

$128.23M

Main Segment (Y)

Development revenue

Adaptimmune Therapeutics Revenue by Period

Adaptimmune Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$60.28M122.05%
2022-12-31$27.15M341.50%
2021-12-31$6.15M55.36%
2020-12-31$3.96M252.76%
2019-12-31$1.12M-98.11%
2018-12-31$59.51M57.28%
2017-12-31$37.83M166.47%
2016-12-31$14.20M32.43%
2015-06-30$10.72M1673.21%
2014-06-30$604.63K100.00%
2013-06-30--

Adaptimmune Therapeutics generated $60.28M in revenue during NA 2023, up 122.05% compared to the previous quarter, and up 101.30% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$128.23M2158.38%
2024-03-31$5.68M2336.82%
2023-12-31$233.01K-96.82%
2023-09-30$7.32M42.67%
2023-06-30$5.13M-89.22%
2023-03-31$47.60M331.64%
2022-12-31$11.03M57.39%
2022-09-30$7.01M26.53%
2022-06-30$5.54M54.91%
2022-03-31$3.58M152.29%
2021-12-31$1.42M17.79%
2021-09-30$1.20M-61.13%
2021-06-30$3.10M613.13%
2021-03-31$434.00K-71.11%
2020-12-31$1.50M25.90%
2020-09-30$1.19M137.65%
2020-06-30$502.00K-34.03%
2020-03-31$761.00K4.53%
2019-12-31$728.00K207.17%
2019-09-30$237.00K50.96%
2019-06-30$157.00K100.00%
2019-03-31--100.00%
2018-12-31$1.48M-96.37%
2018-09-30$40.79M351.34%
2018-06-30$9.04M10.27%
2018-03-31$8.20M91.94%
2017-12-31$4.27M-84.29%
2017-09-30$27.18M672.08%
2017-06-30$3.52M23.24%
2017-03-31$2.86M-66.53%
2016-12-31$8.54M253.31%
2016-09-30$2.42M636.59%
2016-06-30$328.00K-88.76%
2016-03-31$2.92M-25.94%
2015-09-30$3.94M100.00%
2015-03-31--100.00%
2014-12-31$2.27M47.92%
2014-09-30$1.53M-

Adaptimmune Therapeutics generated $128.23M in revenue during Q2 2024, up 2158.38% compared to the previous quarter, and up 269.39% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue Breakdown

Adaptimmune Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Development revenue$60.28M$27.15M$6.15M--
Development And Service---$3.96M$1.12M

Adaptimmune Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Development revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Dec 18Sep 18
Development revenue$40.90M$7.55M$5.13M$47.60M$11.03M$7.01M$5.54M$3.58M$1.20M-----------
Development And Service---------$3.10M$434.00K$1.50M$1.19M$502.00K$761.00K$728.00K$237.00K$157.00K$1.48M$1.68M
License And Service-------------------$39.11M

Adaptimmune Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Development revenue (100.00%).

Adaptimmune Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SGMOSangamo Therapeutics$176.23M$356.00K
ADAPAdaptimmune Therapeutics$60.28M$128.23M
PIRSPieris Pharmaceuticals$42.81M-
AGIOAgios Pharmaceuticals$26.82M$8.96M
MREOMereo BioPharma Group$10.00M-
STOKStoke Therapeutics$8.78M$4.89M
AFMDAffimed$8.28M$155.00K
PLRXPliant Therapeutics$1.58M-
FIXXQ32 Bio$1.16M-
CRVSCorvus Pharmaceuticals--
APTOAptose Biosciences--
BDTXBlack Diamond Therapeutics--
INKTMiNK Therapeutics--
PDSBPDS Bio--
NKTXNkarta--
LPTXLeap Therapeutics--
ACETAdicet Bio--

ADAP Revenue FAQ

What is Adaptimmune Therapeutics’s yearly revenue?

Adaptimmune Therapeutics's yearly revenue for 2023 was $60.28M, representing an increase of 122.05% compared to 2022. The company's yearly revenue for 2022 was $27.15M, representing an increase of 341.50% compared to 2021. ADAP's yearly revenue for 2021 was $6.15M, representing an increase of 55.36% compared to 2020.

What is Adaptimmune Therapeutics’s quarterly revenue?

Adaptimmune Therapeutics's quarterly revenue for Q2 2024 was $128.23M, a 2158.38% increase from the previous quarter (Q1 2024), and a 2399.63% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.68M, a 2336.82% increase from the previous quarter (Q4 2023), and a -88.07% decrease year-over-year (Q1 2023). ADAP's quarterly revenue for Q4 2023 was $233.01K, a -96.82% decrease from the previous quarter (Q3 2023), and a -97.89% decrease year-over-year (Q4 2022).

What is Adaptimmune Therapeutics’s revenue growth rate?

Adaptimmune Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 880.34%, and for the last 5 years (2019-2023) was 5272.64%.

What are Adaptimmune Therapeutics’s revenue streams?

Adaptimmune Therapeutics's revenue streams in c 23 are Development revenue

What is Adaptimmune Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Adaptimmune Therapeutics was Development revenue. This segment made a revenue of $60.28M, representing 100.00% of the company's total revenue.